



Correction to: Fremanezumab: First Global Approval

Sheridan M. Hoy¹

Published online: 11 March 2019
© Springer Nature 2019

Correction to: Drugs (2018) 78:1829–1834
<https://doi.org/10.1007/s40265-018-1004-5>

The article Fremanezumab: First Global Approval, written by Sheridan M. Hoy, was originally published Online First without open access. After publication in volume 78, issue 17, pages 1829–1834 Teva Pharmaceuticals requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Teva Pharmaceuticals. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any non-commercial use, duplication, adaptation, distribution and

reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article has been updated.

Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s40265-018-1004-5>.

✉ Sheridan M. Hoy
dru@adis.com

¹ Springer, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand